Selenium Thyroid Randomized Trial: What the Evidence Says

Quick Answer

Selenium Thyroid Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 research article.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• As a result, many patients will experience ongoing autoimmunity, abnormal thyroid morphology, or residual symptoms after their hormone replacement is optimized. [Berisha-Muharremi Venera (2026); evidence level 1]
• In the thyroid gland, the increased perfusion may improve the viability of thyroid follicular cells, the synthesis of hormones, and tissue regeneration. [Berisha-Muharremi Venera (2026); evidence level 1]
• Se deficiency is linked to an increased risk of and progression of inflammatory diseases, especially chronic autoimmune thyroiditis (AIT), and primarily Hashimoto's thyroiditis (HT) and Graves' disease (GD). [Duntas Leonidas H (2026); evidence level 4]
• Se supplementation has been used in both conditions with evidence-based positive results in HT but questionable results in GD (,,). [Duntas Leonidas H (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For selenium thyroid randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Berisha-Muharremi Venera (2026). Photobiomodulation Therapy in Chronic Autoimmune Thyroiditis: A Systematic Review of Molecular Mechanisms and Clinical Applications. DOI: 10.3390/ijms27073007. PMCID: PMC13073973. PMID: 41977196. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13073973/
• Duntas Leonidas H (2026). The caprices of a trace element: selenium’s considerable effects on Hashimoto’s thyroiditis, though few on Graves’ disease. DOI: 10.1530/ETJ-26-0009. PMCID: PMC12927446. PMID: 41677203. License: https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Attribution-NonCommercial 4.0 International License..... https://pmc.ncbi.nlm.nih.gov/articles/PMC12927446/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.